REBYOTA: payments to doctors
Payments that named REBYOTA as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.
- Total reported
- $2.3M
- Providers
- 8,186
- Transactions
- 19,072
- Average per transaction
- $122
The per-transaction average — $122 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 8,186 providers the average total is $284, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| Ferring Pharmaceuticals Inc. | $2,100,071 | 90.2% |
| Rebiotix Inc. | $150,913 | 6.5% |
| Ferring Microbiome Inc. | $51,415 | 2.2% |
| Ferring Pharmaceuticals AS | $14,680 | 0.6% |
| Ferring International Center SA | $7,155 | 0.3% |
| Ferring Inc. | $2,790 | 0.1% |